Preeclampsia and maternal cardiovascular disease: Consequence or predisposition?

Journal of Vascular Research

Volumn 51, Issue 4, 2014, Pages 290-304

  Osol, George ^a   Bernstein, Ira ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Cardiovascular disease; Endothelial damage; Gestational interval; Preeclampsia; Pregnancy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSINOGEN; BIOLOGICAL MARKER; BRADYKININ B2 RECEPTOR; ENDOGLIN; HEMOGLOBIN F; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MICRORNA; PHOSPHOLIPID ANTIBODY; PLACENTA PROTEIN; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1;

ARTERIAL WALL THICKNESS; BLOOD PRESSURE MONITORING; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; FLOW MEDIATED DILATION; GENE EXPRESSION; GENETIC PREDISPOSITION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; LONG TERM SURVIVAL; MATERNAL DISEASE; MATERNAL MORTALITY; MEAN ARTERIAL PRESSURE; PHENOTYPE; PLACENTA CIRCULATION; PLASMA VOLUME; PREECLAMPSIA; PREGNANCY; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASOCONSTRICTION; VASODILATATION; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PUERPERIUM;

BIOLOGICAL MARKERS; FEMALE; HUMANS; POSTPARTUM PERIOD; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 84908871770     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000367627     Document Type: Review

References (140)

1. Dover GJ: The Barker hypothesis: how pediatricians will diagnose and prevent common adult-onset diseases. Trans Am Clin Climatol Assoc 2009; 120: 199-207.
2. Barker DJ: Fetal origins of cardiovascular disease. Ann Med 1999; 31(suppl 1):3-6.
3. Williams D: Pregnancy: a stress test for life. Curr Opin Obstet Gynecol 2003; 15: 465-471.
4. Gammill HS, et al: Cellular fetal microchimerism in preeclampsia. Hypertension 2013; 62: 1062-1067.
5. Abbas AE, Lester SJ, Connolly H: Pregnancy and the cardiovascular system. Int J Cardiol 2005; 98: 179-189.
6. Brunton PJ, Arunachalam S, Russel JA: Control of neurohypophysial hormone secretion, blood osmolality and volume in pregnancy. J Physiol Pharmacol 2008; 59:(suppl 8):27-45.
7. O'Day MP: Cardio-respiratory physiological adaptation of pregnancy. Semin Perinatol 1997; 21: 268-275.
8. Powe CE, Levine RJ, Karumanchi SA: Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856-2869.
9. Dhawan V, Brookes ZL, Kaufman S: Longterm effects of repeated pregnancies (multiparity) on blood pressure regulation. Cardiovasc Res 2004; 64: 179-186.
10. Dhawan V, Brookes ZL, Kaufman S: Repeated pregnancies (multiparity) increases venous tone and reduces compliance. Am J Physiol Regul Integr Comp Physiol 2005; 289:R23-R28.
11. Tawfik HE, et al: Role of oxidative stress in multiparity-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 295: H1736-H1742.
12. Williams D: Long-term complications of preeclampsia. Semin Nephrol 2011; 31: 111-122.
13. Rosser ML, Katz NT: Preeclampsia: an obstetrician's perspective. Adv Chronic Kidney Dis 2013; 20: 287-296.
14. Al-Jameil N, et al: A brief overview of preeclampsia. J Clin Med Res 2014; 6: 1-7.
15. Navaratnam K, et al: A multi-centre phase IIA clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED). BMC Pregnancy Childbirth 2013; 13: 226.
16. Staff AC, et al: Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013; 61: 932-942.
17. Brittain PC, Bayliss P: Partial hydatidiform molar pregnancy presenting with severe preeclampsia prior to twenty weeks gestation: a case report and review of the literature. Mil Med 1995; 160: 42-44.
18. Sibai BM: Imitators of severe pre-eclampsia. Semin Perinatol 2009; 33: 196-205.
19. Sibai BM: Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol 2012; 206: 470-475.
20. Santos VM, et al: Late-onset postpartum eclampsia: still a diagnostic dilemma? Hong Kong Med J 2008; 14: 60-63.
21. Appenzeller S, et al: HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum 2011; 41: 517-523.
22. Haram K, Svendsen E, Abildgaard U: The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth 2009; 9: 8.
23. Baird JN Jr: Eclampsia in a lowland gorilla. Am J Obstet Gynecol 1981; 141: 345-346.
24. Stout C, Lemmon WB: Glomerular capillary endothelial swelling in a pregnant chimpanzee. Am J Obstet Gynecol 1969; 105: 212-215.
25. Thornton JG, Onwude JL: Convulsions in pregnancy in related gorillas. Am J Obstet Gynecol 1992; 167: 240-241.
26. Palmer AE, et al: Spontaneous preeclamptic toxemia of pregnancy in the patas monkey (Erythrocebus patas). Lab Anim Sci 1979; 29: 102-106.
27. Ramsay MM, et al: Proteinuric hypertension in a pregnant baboon: was this pre-eclampsia? J Med Primatol 1997; 26: 207-212.
28. Granger JP, et al: Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular- renal dysfunction in response to placental ischemia. Methods Mol Med 2006; 122: 383-392.
29. Neerhof MG, et al: Pathophysiology of chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat. Hypertens Pregnancy 2011; 30: 28-36.
30. Hale SA, et al: Reduced NO signaling during pregnancy attenuates outward uterine artery remodeling by altering MMP expression and collagen and elastin deposition. Am J Physiol Heart Circ Physiol 2011; 301:H1266-H1275.
31. Geusens N, et al: Endovascular trophoblast invasion, spiral artery remodelling and uteroplacental haemodynamics in a transgenic rat model of pre-eclampsia. Placenta 2008; 29: 614-623.
32. Carter AM: Animal models of human placentation - a review. Placenta 2007; 28(suppl A): S41-S47.
33. McCarthy FP, et al: Animal models of preeclampsia; uses and limitations. Placenta, 2011; 32: 413-419.
34. Verdonk K, et al: The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond) 2014; 126: 537-544.
35. Australasian Society for the Study of Hypertension in Pregnancy: Management of hypertension in pregnancy: executive summary. Med J Aust 1993; 158: 700-702.
36. Magee LA, et al: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30(suppl 3):S1-S48.
37. Roberts JM, Hubel CA: The two-stage model of preeclampsia: variations on the theme. Placenta 2009; 30(suppl A):S32-S37.
38. Palei AC, et al: Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf) 2013; 208: 224- 233.
39. Eastabrook G, Brown M, Sargent I: The origins and end-organ consequence of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25: 435-447.
40. Staff AC, et al: Preeclampsia and uteroplacental acute atherosis: immune and inflammatory factors. J Reprod Immunol 2014; 101- 102: 120-126.
41. Bonney EA: Preeclampsia: a view through the danger model. J Reprod Immunol 2007; 76: 68-74.
42. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
43. Matzinger P: An innate sense of danger. Semin Immunol 1998; 10: 399-415.
44. Matzinger P: Introduction to the series. Danger model of immunity. Scand J Immunol 2001; 54: 2-3.
45. Redman CW, Sargent IL: Immunology of preeclampsia. Am J Reprod Immunol 2010; 63: 534-543.
46. Redman CW, Sargent IL: Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30(suppl A):S38-S42.
47. Skjaerven R, Wilcox AJ, Lie RT: The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002; 346: 33-38.
48. Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC: Effects of birth spacing on maternal health: a systematic review. Am J Obstet Gynecol 2007; 196: 297-308.
49. Deen ME, et al: Risk factors for preeclampsia in multiparous women: primipaternity versus the birth interval hypothesis. J Matern Fetal Neonatal Med 2006; 19: 79-84.
50. Mostello D, et al: Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol 2002; 187: 425-429.
51. Basso O, Christensen K, Olsen J: Higher risk of pre-eclampsia after change of partner. An effect of longer interpregnancy intervals? Epidemiology 2001; 12: 624-629.
52. El-Behery MM, et al: Reproductive performance in the next pregnancy for nulliparous women with history of first trimester spontaneous abortion. Arch Gynecol Obstet 2013; 288: 939-944.
53. Zhu BP, Le T: Effect of interpregnancy interval on infant low birth weight: a retrospective cohort study using the Michigan Maternally Linked Birth Database. Matern Child Health J 2003; 7: 169-178.
54. Love ER, Bhattacharya S, Smith NC: Effect of interpregnancy interval on outcomes of pregnancy after miscarriage: retrospective analysis of hospital episode statistics in Scotland. BMJ 2010; 341:c3967.
55. Thomson F, et al: Obstetric outcome in women with subfertility. BJOG 2005; 112: 632-637.
56. Chesley LC: Hypertension in pregnancy: definitions, familial factor, and remote prognosis. Kidney Int 1980; 18: 234-240.
57. Chesley LC: Remote prognosis after eclampsia. Perspect Nephrol Hypertens 1976; 5: 31-40.
58. Fisher KA, et al: Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981; 60: 267-276.
59. Brown MC, et al: Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013; 28: 1-19.
60. Goynumer G, et al: Vascular risk in women with a history of severe preeclampsia. J Clin Ultrasound 2013; 41: 145-150.
61. Lykke JA, et al: Mortality of mothers from cardiovascular and non-cardiovascular causes following pregnancy complications in first delivery. Paediatr Perinat Epidemiol 2010; 24: 323-330.
62. Mangos GJ, et al: Markers of cardiovascular disease risk after hypertension in pregnancy. J Hypertens 2012; 30: 351-358.
63. McDonald SD, et al: Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156: 918-930.
64. Mongraw-Chaffin ML, Cirillo PM, Cohn BA: Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010; 56: 166-171.
65. Irgens HU, et al: Long-term mortality of mothers and fathers after pre-eclampsia: population- based cohort study. BMJ 2001; 323: 1213-1217.
66. Vikse BE, et al: Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800-809.
67. Melchiorre K, et al: Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension 2011; 58: 709-715.
68. Innes KE, Weitzel L, Laudenslager M: Altered metabolic profiles among older mothers with a history of preeclampsia. Gynecol Obstet Invest 2005; 59: 192-201.
69. Valdiviezo C, Garovic VD, Ouyang P: Preeclampsia and hypertensive disease in pregnancy: their contributions to cardiovascular risk. Clin Cardiol 2012; 35: 160-165.
70. Hladunewich MA, et al: Postpartum assessment of the renin angiotensin system in women with previous severe, early-onset preeclampsia. J Clin Endocrinol Metab 2011; 96: 3517-3524.
71. Yinon Y, et al: Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010; 122: 1846-1853.
72. Abdul-Karim R, Assalin S: Pressor response to angiotonin in pregnant and nonpregnant women. Am J Obstet Gynecol 1961; 82: 246-251.
73. Gant NF, et al: A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52: 2682-2689.
74. Chesley LC: Vascular reactivity in normal and toxemic pregnancy. Clin Obstet Gynecol 1966; 9: 871-881.
75. Shah DM: Preeclampsia: new insights. Curr Opin Nephrol Hypertens 2007; 16: 213-220.
76. AbdAlla S, Lother H, Quitterer U: AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000; 407: 94-98.
77. AbdAlla S, et al: Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003-1009.
78. Xia Y, Kellems RE: Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res 2013; 113: 78-87.
79. Wallukat G, et al: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103: 945-952.
80. Wenzel K, et al: Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 2011; 58: 77-84.
81. Yang X, et al: Autoantibodies Isolated from preeclamptic patients induce endothelial dysfunction via interaction with the angiotensin II AT1 receptor. Cardiovasc Toxicol 2014; 14: 21-29.
82. Hubel CA, et al: Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007; 49: 612-617.
83. Elliott SE, et al: Characterization of antibody specificities associated with preeclampsia. Hypertension 2014; 63: 1086-1093.
84. Lommerse T, et al: Endothelium-dependent vasodilatation in formerly preeclamptic women correlates inversely with body mass index and varies independently of plasma volume. Reprod Sci 2007; 14: 765-770.
85. Germain AM, et al: Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension 2007; 49: 90-95.
86. Chambers JC, et al: Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285: 1607-1612.
87. Hamad RR, et al: Impaired endothelial function and elevated levels of pentraxin 3 in early- onset preeclampsia. Acta Obstet Gynecol Scand 2012; 91: 50-56.
88. Paez O, et al: Parallel decrease in arterial distensibility and in endothelium-dependent dilatation in young women with a history of pre-eclampsia. Clin Exp Hypertens 2009; 31: 544-552.
89. Agatisa PK, et al: Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004; 286:H1389-H1393.
90. Tyldum EV, et al: Maternal left ventricular and endothelial functions in preeclampsia. Acta Obstet Gynecol Scand 2012; 91: 566-573.
91. Lampinen KH, et al: Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens 2006; 24: 751-756.
92. Lampinen KH, et al: Increased plasma norepinephrine levels in previously pre-eclamptic women. J Hum Hypertens 2014; 28: 269-273.
93. Mori T, et al: Differences in vascular reactivity between pregnant women with chronic hypertension and preeclampsia. Hypertens Res 2014; 37: 145-150.
94. Kublickiene K, et al: Small artery function in women at reproductive age and with a history of early-onset preeclampsia. Reprod Sci 2013; 20: 93A.
95. Myatt L, Miodovnik M: Prediction of preeclampsia. Semin Perinatol 1999; 23: 45-57.
96. Zhou Y, et al: Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest 2013; 123: 2862-2872.
97. Borzychowski AM, Sargent IL, Redman CW: Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006; 11: 309-316.
98. Bernstein IM, et al: Angiotensinogen genotype and plasma volume in nulligravid women. Obstet Gynecol 1998; 92: 171-173.
99. Bernstein IM, et al: Intolerance to volume expansion: a theorized mechanism for the development of preeclampsia. Obstet Gynecol 1998; 92: 306-308.
100. Bernstein IM, et al: Relationship of plasma volume to sympathetic tone in nulliparous women. Am J Obstet Gynecol 2003; 188: 938-942.
101. Damron DP, et al: Platelet activation, sympathetic tone, and plasma volume in nulligravid women of reproductive age. Obstet Gynecol 2004; 103: 931-936.
102. Bernstein IM, et al: The relationship of plasma volume, sympathetic tone, and proinflammatory cytokines in young healthy nonpregnant women. Reprod Sci 2009; 16: 980- 985.
103. Damron DP, et al: Uterine blood flow response to alpha-adrenergic blockade in nulligravid women of reproductive age. J Soc Gynecol Investig 2004; 11: 388-392.
104. McBride CA, et al: The relationship of a family history for hypertension, myocardial infarction, or stroke with cardiovascular physiology in young women. Reprod Sci 2014; 21: 509-516.
105. Hale S, et al: Pulse pressure and arterial compliance prior to pregnancy and the development of complicated hypertension during pregnancy. Reprod Sci 2010; 17: 871-877.
106. Hale SA, et al: Prepregnancy vascular dysfunction in women who subsequently develop hypertension during pregnancy. Pregnancy Hypertens 2013; 3: 140-145.
107. Aardenburg R, et al: Low plasma volume following pregnancy complicated by pre-eclampsia predisposes for hypertensive disease in a next pregnancy. BJOG 2003; 110: 1001- 1006.
108. Aardenburg R, et al: A low plasma volume in formerly preeclamptic women predisposes to the recurrence of hypertensive complications in the next pregnancy. J Soc Gynecol Investig 2006; 13: 598-603.
109. Bernstein IM, et al: The influence of pregnancy on arterial compliance. Obstet Gynecol 2005; 105: 621-625.
110. Mikolajczyk RT, et al: Effects of interpregnancy interval on blood pressure in consecutive pregnancies. Am J Epidemiol 2008; 168: 422-426.
111. Bernstein IM, Hale S, Badger G: Evidence for persistent vascular remodeling following pregnancy. Am J Obstetr Gynecol 2014; 210:S400.
112. Romundstad PR, et al: Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122:579-584.
113. Bezerra PC, et al: Family history of hypertension as an important risk factor for the development of severe preeclampsia. Acta Obstet Gynecol Scand 2010; 89: 612-617.
114. Sibai B, Dekker G, Kupferminc M: Pre-eclampsia. Lancet 2005; 365: 785-799.
115. Poon LC, et al: Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010; 24: 104-110.
116. van Dijk M, Oudejans C: (Epi)genetics of pregnancy-associated diseases. Front Genet 2013; 4: 180.
117. Duckitt K, Harrington D: Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330: 565.
118. Magnussen EB, et al: Prepregnancy cardiovascular risk factors as predictors of preeclampsia: population-based cohort study. BMJ 2007; 335: 978.
119. Rasmussen S, Irgens LM: Pregnancy-induced hypertension in women who were born small. Hypertension 2007; 49: 806-812.
120. Innes KE, et al: Association of a woman's own birth weight with her subsequent risk for pregnancy-induced hypertension. Am J Epidemiol 2003; 158: 861-870.
121. Naljayan MV, Karumanchi SA: New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis 2013; 20: 265-270.
122. Hagmann H, et al: The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 2012; 58: 837-845.
123. Wang A, Rana S, Karumanchi SA: Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-158.
124. Maynard SE, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
125. LaMarca BD, et al: Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep 2007; 9: 480-485.
126. Redman CW, et al: Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012; 33(suppl):S48-S54.
127. van der Post JA, et al: The functions of microparticles in pre-eclampsia. Semin Thromb Hemost 2011; 37: 146-152.
128. Kim YJ: Pathogenesis and promising noninvasive markers for preeclampsia. Obstet Gynecol Sci 2013; 56: 2-7.
129. Stubert J, et al: miRNA expression profiles determined in maternal sera of patients with HELLP syndrome. Hypertens Pregnancy 2014; 33: 215-235.
130. Conde-Agudelo A, Villar J, Lindheimer M: World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104: 1367-1391.
131. Tyldum EV, Romundstad PR, Slordahl SA: Pre-pregnancy physical activity and preeclampsia risk: a prospective populationbased cohort study. Acta Obstet Gynecol Scand 2010; 89: 315-320.
132. Thorne-Lyman A, Fawzi WW: Vitamin D during pregnancy and maternal, neonatal and infant health outcomes: a systematic review and meta-analysis. Paediatr Perinat Epidemiol 2012; 26(suppl 1):75-90.
133. Thangaratinam S, et al: Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25: 419-433.
134. Scholten RR, et al: Cardiovascular effects of aerobic exercise training in formerly preeclamptic women and healthy parous control subjects. Am J Obstet Gynecol 2014.
135. Genest DS, et al: Impact of exercise training on preeclampsia: potential preventive mechanisms. Hypertension 2012; 60: 1104-1109.
136. Kasawara KT, et al: Exercise and physical activity in the prevention of pre-eclampsia: systematic review. Acta Obstet Gynecol Scand 2012; 91: 1147-1157.
137. Anderson UD, et al: Review: Biochemical markers to predict preeclampsia. Placenta 2012; 33(suppl):S42-S47.
138. Masoura S, et al: Biomarkers in pre-eclampsia: a novel approach to early detection of the disease. J Obstet Gynaecol 2012; 32: 609- 616.
139. Sanchez-Ramos L, et al: The protein-to-creatinine ratio for the prediction of significant proteinuria in patients at risk for preeclampsia: a meta-analysis. Ann Clin Lab Sci 2013; 43: 211-220.
140. Forest JC, et al: Candidate biochemical markers for screening of pre-eclampsia in early pregnancy. Clin Chem Lab Med 2012; 50: 973-984.